Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

Pellegrino Musto, Francesco Lanza, Enrico Balleari, Alberto Grossi, Antonietta Falcone, Grazia Sanpaolo, Carlo Bodenizza, Potito Rosario Scalzulli, Antonio La Sala, Diana Campioni, Riccardo Ghio, Nicola Cascavilia, Angelo Michele Carella

Research output: Contribution to journalArticlepeer-review


Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 μg s.c. for at least 12 weeks. Fifteen patients (40-5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin

Original languageEnglish
Pages (from-to)204-209
Number of pages6
JournalBritish Journal of Haematology
Issue number2
Publication statusPublished - Jan 2005


  • Anaemia
  • Darbepoetin
  • Erythropoietin
  • Myelodysplastic syndromes
  • Transfusion

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this